methyl (2R,5R)-5-hydroxypiperidine-2-carboxylate | 797801-72-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: methyl (2R,5R)-5-hydroxypiperidine-2-carboxylate
• CAS: 797801-72-0
• 化学式: C₇H₁₃NO₃
• 分子量: 159.185
• InChiKey: KKBQWQJVUYTRDO-PHDIDXHHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  58.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  methyl (2R,5R)-5-hydroxypiperidine-2-carboxylate 在 盐酸 、 锂硼氢 、 水 、 三乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 、 potassium hydroxide 、 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 乙醚 、 二氯甲烷 、 乙腈 为溶剂， 反应 129.75h， 生成 lithium 12-((2R,5R)-2-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-5-hydroxypiperidin-1-yl)-12-oxododecanoate
  参考文献：
  名称：

  [EN] TARGETED NUCLEIC ACID CONJUGATE COMPOSITIONS
  [FR] COMPOSITIONS DE CONJUGUÉS D'ACIDES NUCLÉIQUES CIBLÉS

  摘要：

  这项发明提供了包括靶向基团、核酸和可选连接基团的共轭物，以及用于制备这些共轭物的合成中间体和合成方法。这些共轭物可用于将治疗性核酸靶向肝脏，并用于治疗包括肝炎（如乙型肝炎和丙型肝炎）在内的肝脏疾病。

  公开号：

  WO2017177326A1
• 作为产物：
  描述：

  N-[苄氧羰基]-D-谷氨酸 1-甲基酯 在 palladium on activated charcoal dirhodium tetraacetate 、 sodium tetrahydroborate 、 氢气 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 、 乙醚 、 苯 为溶剂， 生成 methyl (2R,5R)-5-hydroxypiperidine-2-carboxylate
  参考文献：
  名称：

  (2S,5R/2R,5S)-Aminoethylpipecolyl aepip-aegPNA chimera: synthesis and duplex/triplex stability

  摘要：

  This article reports the design and facile synthesis of novel chiral six-membered PNA analogues (2S,5R/2R,5S)-1-(N-Boc-aminoethyl)-5-(thymin-1-yl)pipecolic acid, aepipPNA IV that upon incorporation into standard aegPNA sequences effected stabilization of complexes with complementary target DNA. Substitution of aegPNA unit by the designed monomer at the C-terminus was more effective than substitution at N-terminus. The stabilizing behaviour improved with degree of substitution and was found to be dependent on their relative positions in the sequence. The six-membered piperidine ring in the design may freeze the rigid chair conformations and the relative stereochemistry of the substituents may in effect direct the complex formation with DNA/RNA by sequence-specific nucleobase recognition. In the present aepipPNA analogues, the L-trans stereochemical disposition of the substituents seems to lead to the favorable pre-organization of the PNA oligomers for complex formation with DNA. The results reported here further expand the repertoire of cyclic PNA analogues. (C) 2004 Published by Elsevier Ltd.

  DOI：

  10.1016/j.tet.2004.07.080

文献信息

• [EN] TARGETED NUCLEIC ACID CONJUGATE COMPOSITIONS<br/>[FR] COMPOSITIONS DE CONJUGUÉS D'ACIDES NUCLÉIQUES CIBLÉS
  申请人：PROTIVA BIOTHERAPEUTICS INC

  公开号：WO2017177326A1

  公开（公告）日：2017-10-19

  The invention provides conjugates that comprise a targeting moiety, a nucleic acid, and optional linking groups as well as synthetic intermediates and synthetic methods useful for preparing the conjugates. The conjugates are useful to target therapeutic nucleic acids to the liver and to treat liver diseases including hepatitis (e.g. hepatitis B and hepatitis D).

  这项发明提供了包括靶向基团、核酸和可选连接基团的共轭物，以及用于制备这些共轭物的合成中间体和合成方法。这些共轭物可用于将治疗性核酸靶向肝脏，并用于治疗包括肝炎（如乙型肝炎和丙型肝炎）在内的肝脏疾病。
• [EN] TARGETED COMPOSITIONS<br/>[FR] COMPOSITIONS CIBLÉES
  申请人：ARBUTUS BIOPHARMA CORP

  公开号：WO2018191278A3

  公开（公告）日：2018-11-22
• [EN] METHODS FOR TREATING HEPATITIS B INFECTIONS<br/>[FR] MÉTHODES DE TRAITEMENT DES INFECTIONS DE TYPE HÉPATITE B
  申请人：ARBUTUS BIOPHARMA CORP

  公开号：WO2019051257A3

  公开（公告）日：2020-03-26
• TARGETED NUCLEIC ACID CONJUGATE COMPOSITIONS
  申请人：ARBUTUS BIOPHARMA CORPORATION

  公开号：US20190160176A1

  公开（公告）日：2019-05-30

  The invention provides conjugates that comprise a targeting moiety, a nucleic acid, and optional linking groups as well as synthetic intermediates and synthetic methods useful for preparing the conjugates. The conjugates are useful to target therapeutic nucleic acids to the liver and to treat liver diseases including hepatitis (e.g. hepatitis B and hepatitis D).
• TARGETED COMPOSITIONS
  申请人：ARBUTUS BIOPHARMA CORPORATION

  公开号：US20200407724A1

  公开（公告）日：2020-12-31

  The invention provides certain nucleic acids (e.g., double stranded siRNA molecules), as well as conjugates that comprise a targeting moiety, a double stranded siRNA, and optional linking groups. Certain embodiments also provide synthetic methods useful for preparing the conjugates. The conjugates are useful to target therapeutic double stranded siRNA to the liver and to treat liver diseases including hepatitis (e.g. hepatitis B and hepatitis D).